Stop me if you've heard this joke before: "Two political parties walk into a bar; both point the finger at each other for the country's fiscal mess, yet neither is willing to budge an inch from their underlying views..." My guess is you've heard this one all too often and it's not even funny anymore... because the truth rarely is.
The highly anticipated sequestration, aimed at removing $1.1 trillion out of the federal budget over the next decade, kicked into effect on March 1, and is set to gradually, but decisively, remove $85 billion from the federal budget. These cuts are going to come from all walks of government – from USDA inspectors, to military spending, and even entitlement programs like Medicare, which is expected to see approximately a 2% reduction in reimbursements.
Today, I want to take a closer look at how sequestration could impact the health care sector.
As you might imagine, many of the effects of removing government funding tend to be negative -- but it's not as cut-and-dried as it might appear on the surface.
How it'll affect safety
The most immediate impact of sequestration appears to be whether patient and consumer safety will be affected negatively. On the surface I'd say this is a distinct possibility with the Centers for Disease Control and Prevention seeing nearly a $450 million cut in its budget and the FDA, whose expenses are predominantly tied to its personnel costs, alluding that a $318 million reduction in funds will result in layoffs or furloughs totaling 2,100 USDA food inspectors.
Food safety looks like a clear loser with Tyson Foods (NYSE:TSN) and Smithfield Foods projected to suffer from USDA furloughs. By law, processed meat cannot be sold in stores without having been inspected, leaving Tyson and Smithfield in a big bind come the summer time when these furloughs are expected to hit the hardest. The end result may be less meat on supermarket shelves and higher prices because of it.
The bigger concern here actually stems from the CDC's reduced budget. As GlobalData analysts noted this past week, one of the CDC's primary functions is to provide educational and preventative materials and products to curb the spread of infectious diseases such as hepatitis and HIV. A lack of funding here could result in higher occurrences of these infectious diseases. However, I disagree with their analysis that this negative occurrence could have the hidden benefit of driving down costs as providers opt for cheaper drugs in the HIV space, hurting the launch of expensive new offerings like . Gilead Sciences' (NASDAQ:GILD) four-in-one HIV medication, Stribild. Made with all in-house compounds, if Stribild supplants Gilead's current best-selling HIV treatment, Atripla, it will result in higher margins for the company. Keeping things in perspective, I wouldn't expect a huge spike in HIV occurrences, but I wouldn't be surprised if documented cases rose year-over-year.
How it'll affect research and development
Research and development in pharmaceuticals, biotech, and life sciences looks like it'll be a bit of a mixed bag. The National Institutes of Health is expected to be dealt a big blow with a reduction in funding of more than $1.6 billion. That means somewhere in the neighborhood of 2,000 fewer grants will be issued. In addition, a reduction in FDA budgets, while being dealt with largely on the food inspection front, could translate to slower drug and device approval. That would be bad news for potential drugs that aren't set to be examined by the FDA until the latter half of 2013, including GlaxoSmithKline and Theravance's (NASDAQ: THRX) revolutionary long-term COPD treatment, Anoro, which I declared as a game-changing drug hopeful late last year.
On the other hand, a reduction in grants from the NIH could spur consolidation in a very thin biotechnology and life sciences sector which I'd view as a positive. Life Technologies (NASDAQ: LIFE), for instance, announced in January that it was conducting its annual strategic review, implying to investors that a sale of the company was being pondered. Although a sale may not come to fruition with bidder Thermo Fisher Scientific no longer in the running after Life Tech's huge run-up in price, consolidation could become increasingly common as grant funds decrease.
Will the sequester affect your bottom line?
The primary question most people have is how sequestration could affect their personal care. Ultimately, it shouldn't result in any immediate out-of-pocket costs -- but that doesn't mean you're out of the woods, either.
Most social programs -- including Social Security, Medicaid, and unemployment benefits -- are exempt from the budget cuts. Even Medicare beneficiaries were spared the reduction, with lawmakers instead voting to cut 2% out of the budgets of those reimbursed by Medicare. This means that health-benefits companies and hospitals could feel a bit of a pinch. Humana (NYSE:HUM) is a perfect example of a company expected to suffer from the implementation of the sequester. Humana's Medicare Advantage business currently accounts for 63.5% of total sales. With reimbursements expected to be down 2%, it's going to be extremely difficult for Humana to grow its top-line numbers. That would be all the more reason to expect Medicare-reliant health-benefits providers to do whatever they can to boost premiums.
Do you have a solution to the sequester that we haven't covered at The Fool? Let's hear your take in the comments section below.